Dendritic cell integrin expression patterns regulate inflammation in the rheumatoid arthritis joint

Area of Science:

• Immunology
• Cell Biology
• Rheumatology

Background:

• Immune dysregulation is implicated in rheumatoid arthritis (RA) pathogenesis.
• Altered expression of integrin adhesion receptors on immune cells, particularly dendritic cells (DCs), may contribute to RA development.
• Investigating specific integrin subunits like CD11a and CD11b in RA DCs is crucial for understanding disease mechanisms.

Purpose of the Study:

• To investigate the expression patterns and functional roles of β2 integrin subunits CD11a and CD11b in dendritic cell (DC) subsets from patients with rheumatoid arthritis (RA).
• To compare integrin expression in DCs from RA patients' peripheral blood (PB) and synovial fluid (SF) with healthy controls.
• To model and validate findings in vitro using monocyte-derived DCs (moDCs) and assess the impact on T cell activation.

Main Methods:

• Quantified total and active β2 integrin subunit expression (CD11a, CD11b) in DC subsets from RA patients (PB and SF) and healthy controls (PB).
• Utilized ex vivo stimulation of PB DC subsets and in vitro-generated mature and tolerogenic moDCs to model clinical observations.
• Assessed DC function by analyzing clustering and adhesion, and evaluated T cell activation in DC-T cell co-cultures, including experiments with CD11b blockade.

Main Results:

• DCs in RA synovial fluid exhibited significantly reduced CD11a expression and increased CD11b expression compared to peripheral blood.
• In vitro models showed that tolerogenic moDCs had higher active CD11a and lower active CD11b compared to mature moDCs.
• Blocking CD11b function in co-cultures significantly impaired T cell activation, indicating a pro-inflammatory role.

Conclusions:

• Demonstrated opposing expression of CD11a and CD11b in RA DCs, correlating with inflammatory versus tolerogenic states.
• Identified a T cell stimulatory role for CD11b on DCs in the context of RA.
• Highlighted DC-associated integrins CD11a and CD11b as potential novel therapeutic targets for rheumatoid arthritis intervention.